This company is no longer active
La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !
Humanigen Performance dei guadagni passati
Il passato criteri di controllo 0/6
Humanigen has been growing earnings at an average annual rate of 72.1%, while the Biotechs industry saw earnings growing at 15.9% annually. Revenues have been declining at an average rate of 59% per year.
Informazioni chiave
72.1%
Tasso di crescita degli utili
83.2%
Tasso di crescita dell'EPS
Biotechs Crescita del settore | 17.0% |
Tasso di crescita dei ricavi | -59.0% |
Rendimento del capitale proprio | n/a |
Margine netto | -3,156.8% |
Ultimo aggiornamento sui guadagni | 31 Mar 2023 |
Aggiornamenti sulle prestazioni recenti
Recent updates
Humanigen GAAP EPS of -$0.43 misses by $0.11, revenue of $1.04M beats by $0.69M
Aug 12Humanigen plunges 57% as trial for COVID-19 therapy fails
Jul 13Humanigen jumps over 10% after peer-reviewed data on COVID-19 therapy
Jul 06Humanigen (NASDAQ:HGEN) Has Debt But No Earnings; Should You Worry?
Oct 30Health Check: How Prudently Does Humanigen (NASDAQ:HGEN) Use Debt?
Jul 14Humanigen begins rolling submission for lenzilumab in COVID-19 in U.K.
Jun 14Humanigen submits lenzilumab COVID-19 EUA application to FDA
May 28Humanigen is on the rise after publication of Phase 3 data for COVID-19 therapy
May 05Humanigen, Inc.'s (NASDAQ:HGEN) Intrinsic Value Is Potentially 61% Above Its Share Price
May 05We Might See A Profit From Humanigen, Inc. (NASDAQ:HGEN) Soon
Mar 31Is Humanigen, Inc. (NASDAQ:HGEN) Popular Amongst Institutions?
Feb 26Enrollment completed in Humanigen's late-stage study of lenzilumab in COVID-19
Jan 29Humanigen partners with EVERSANA for launch and commercialization of Lenzilumab for COVID-19 treatment
Jan 11We Think Humanigen (NASDAQ:HGEN) Can Afford To Drive Business Growth
Jan 04Humanigen secures new U.S. patent for lenzilumab
Dec 28Enrollment completed in Humanigen's early-stage ifabotuzumab study in glioblastoma multiforme
Dec 17Humanigen EPS misses by $0.16
Nov 11Humanigen up 7% on partnership with U.S. government to advance lenzilumab for COVID-19
Nov 06Humanigen executes lenzilumab licensing deal in Asia for COVID-19
Nov 03Humanigen Dosing Phase 3 Covid Patients, And Other News: The Good, Bad And Ugly Of Biopharma
Nov 01Dosing underway in lenzilumab late-stage study in COVID-19
Oct 30Dosing underway in mid-stage study of Humanigen's lenzilumab in COVID-19
Oct 29Ripartizione dei ricavi e delle spese
Come Humanigen guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.
Storia dei guadagni e delle entrate
Data | Ricavi | Guadagni | Spese G+A | Spese di R&S |
---|---|---|---|---|
31 Mar 23 | 2 | -54 | 15 | 0 |
31 Dec 22 | 3 | -71 | 16 | 0 |
30 Sep 22 | 3 | -109 | 16 | 26 |
30 Jun 22 | 4 | -152 | 19 | -97 |
31 Mar 22 | 4 | -192 | 23 | -60 |
31 Dec 21 | 4 | -237 | 23 | 0 |
30 Sep 21 | 3 | -235 | 23 | 0 |
30 Jun 21 | 2 | -199 | 25 | 123 |
31 Mar 21 | 1 | -153 | 19 | 59 |
31 Dec 20 | 0 | -90 | 16 | 0 |
30 Sep 20 | 0 | -59 | 13 | 0 |
30 Jun 20 | 0 | -31 | 6 | 1 |
31 Mar 20 | 0 | -10 | 6 | 3 |
31 Dec 19 | 0 | -10 | 6 | 3 |
30 Sep 19 | 0 | -10 | 6 | 3 |
30 Jun 19 | 0 | -10 | 7 | 3 |
31 Mar 19 | 0 | -9 | 7 | 2 |
31 Dec 18 | 0 | -12 | 9 | 2 |
30 Sep 18 | 0 | -13 | 10 | 3 |
30 Jun 18 | 0 | -18 | 10 | 6 |
31 Mar 18 | 0 | -22 | 9 | 9 |
31 Dec 17 | 0 | -22 | 8 | 11 |
30 Sep 17 | 0 | -24 | 7 | 13 |
30 Jun 17 | 0 | -21 | 8 | 11 |
31 Mar 17 | 0 | -27 | 9 | 11 |
31 Dec 16 | 0 | -27 | 8 | 10 |
30 Sep 16 | 0 | -35 | 11 | 11 |
30 Jun 16 | 0 | -37 | 11 | 13 |
31 Mar 16 | 0 | -31 | 11 | 12 |
31 Dec 15 | 0 | -35 | 13 | 15 |
30 Sep 15 | 0 | -32 | 10 | 19 |
30 Jun 15 | 0 | -33 | 10 | 20 |
31 Mar 15 | 0 | -37 | 11 | 24 |
31 Dec 14 | 0 | -38 | 10 | 27 |
30 Sep 14 | 0 | -39 | 10 | 19 |
30 Jun 14 | 0 | -42 | 10 | 14 |
31 Mar 14 | 0 | -44 | 9 | 8 |
31 Dec 13 | 0 | -42 | 8 | 0 |
30 Sep 13 | 0 | -43 | 8 | 0 |
Guadagni di qualità: HGEN.Q is currently unprofitable.
Margine di profitto in crescita: HGEN.Q is currently unprofitable.
Flusso di cassa libero e analisi degli utili
Analisi della crescita degli utili nel passato
Andamento degli utili: Insufficient data to determine if HGEN.Q's year-on-year earnings growth rate was positive over the past 5 years.
Accelerare la crescita: Unable to compare HGEN.Q's earnings growth over the past year to its 5-year average as it is currently unprofitable
Guadagni vs Settore: HGEN.Q is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14.4%).
Rendimento del capitale proprio
ROE elevato: HGEN.Q's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.